ChromaDex CorporationChromaDex CorporationChromaDex Corporation

ChromaDex Corporation

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪197.16 M‬USD
−0.05USD
‪−4.94 M‬USD
‪83.57 M‬USD
‪48.51 M‬
Beta (1Y)
1.07

About ChromaDex Corporation

CEO
Robert N. Fried
Headquarters
Los Angeles
Employees (FY)
106
Founded
1999
FIGI
BBG000BG1J71
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CDXC is 2.61 USD — it has decreased by 9.38% in the past 24 hours. Watch ChromaDex Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ChromaDex Corporation stocks are traded under the ticker CDXC.
CDXC stock has risen by 4.65% compared to the previous week, the month change is a 16.08% fall, over the last year ChromaDex Corporation has showed a 56.29% increase.
We've gathered analysts' opinions on ChromaDex Corporation future price: according to them, CDXC price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch CDXC chart and read a more detailed ChromaDex Corporation stock forecast: see what analysts think of ChromaDex Corporation and suggest that you do with its stocks.
CDXC reached its all-time high on Feb 25, 2021 with the price of 23.66 USD, and its all-time low was 0.33 USD and was reached on Aug 3, 2009. View more price dynamics on CDXC chart.
See other stocks reaching their highest and lowest prices.
CDXC stock is 22.22% volatile and has beta coefficient of 1.07. Track ChromaDex Corporation stock price on the chart and check out the list of the most volatile stocks — is ChromaDex Corporation there?
Today ChromaDex Corporation has the market capitalization of ‪197.16 M‬, it has increased by 4.78% over the last week.
Yes, you can track ChromaDex Corporation financials in yearly and quarterly reports right on TradingView.
ChromaDex Corporation is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
CDXC earnings for the last quarter are −0.01 USD per share, whereas the estimation was −0.02 USD resulting in a 50.00% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about ChromaDex Corporation earnings.
ChromaDex Corporation revenue for the last quarter amounts to ‪22.15 M‬ USD, despite the estimated figure of ‪23.48 M‬ USD. In the next quarter, revenue is expected to reach ‪23.33 M‬ USD.
CDXC net income for the last quarter is ‪−492.00 K‬ USD, while the quarter before that showed ‪114.00 K‬ USD of net income which accounts for −531.58% change. Track more ChromaDex Corporation financial stats to get the full picture.
No, CDXC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 15, 2024, the company has 106.00 employees. See our rating of the largest employees — is ChromaDex Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ChromaDex Corporation EBITDA is ‪−1.21 M‬ USD, and current EBITDA margin is −0.23%. See more stats in ChromaDex Corporation financial statements.
Like other stocks, CDXC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ChromaDex Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ChromaDex Corporation technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ChromaDex Corporation stock shows the buy signal. See more of ChromaDex Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.